Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income

Aquestive Therapeutics

13/05/2026 21:18

Overview

U.S. drug delivery specialist's Q1 revenue rose 66% yr/yr, beating analyst expectations

Net loss for Q1 narrowed, reflecting higher revenue and reduced expenses

Company entered $150 mln debt facility to refinance and extend cash runway

Outlook

Aquestive reaffirms guidance to resubmit Anaphylm NDA in Q3 2026

Company expects 2026 revenue of $46 mln to $50 mln

Aquestive projects 2026 non-GAAP adjusted EBITDA loss of $35 mln to $30 mln

Result Drivers

LICENSE AND ROYALTY REVENUE - Co said Q1 revenue growth was driven by higher license and royalty revenue, mainly from Zevra

MANUFACTURE AND SUPPLY REVENUE - Higher manufacture and supply revenue, led by increased Suboxone sales, contributed to revenue growth

LOWER OPERATING EXPENSES - Reduced research and development and selling, general and administrative expenses helped narrow net loss

Company press release: ID:nGNXcbYQPp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$14.45 mln
$10.90 mln (9 Analysts)
Q1 EPS
-$0.07
Q1 Net Income
-$8.06 mln
Q1 Adjusted EBITDA
Beat
-$1.77 mln
-$10.70 mln (2 Analysts)
Q1 Income From Operations
-$4.20 mln
Q1 Pretax Profit
-$8.06 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $9.00, about 116.3% above its May 12 closing price of $4.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)